• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Advisory Committees

  • Print
  • Share
  • E-mail

Briefing Information for the September 16, 2010 Meeting of the Psychopharmacologic Drugs Advisory Committee

 

Persons with disabilities having problems accessing the PDF file(s) below may call (301) 796-3634 for assistance
 
 
FDA
 
Disclaimer
 
Portions of this document have been determined to be exempt from disclosure under the Freedom of Information Act (the FOIA) (5 U.S.C. § 552).
  
FDA Briefing Information, Vivitrol (Naltrexone for Extended-Release Injectable Suspension), for the September 16, 2010 Meeting of the Psychopharmacologic Drugs Advisory Committee (PDF – 787KB)
 
Errata to the FDA Briefing Information, Vivitrol (Naltrexone for Extended-Release Injectable Suspension), for the September 16, 2010 Meeting of the Psychopharmacologic Drugs Advisory Committee (PDF – 38KB)
 
 
Alkermes, Inc
 
Disclaimer
 
The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
 
Alkermes Briefing Information, Vivitrol (Naltrexone for Extended-Release Injectable Suspension), for the September 16, 2010 Meeting of the Psychopharmacologic Drugs Advisory Committee (PDF – 2.9MB)
 
References list to Alkermes Briefing Information, Vivitrol (Naltrexone for Extended-Release Injectable Suspension), for the September 16, 2010 Meeting of the Psychopharmacologic Drugs Advisory Committee (PDF – 38KB)